Assessment of MR Imaging and CT in Differentiating Hereditary and Nonhereditary Paragangliomas

References

1. 1.↵
   1. Withey SJ,
   2. Perrio S,
   3. Christodoulou D, et al

   . Imaging features of succinate dehydrogenase-deficient pheochromocytoma-paraganglioma syndromes. Radiographics 2019;39:1393–1410 doi:10.1148/rg.2019180151 pmid:31498738

   CrossRefPubMed
2. 2.↵
   1. Williams MD,
   2. Rich TA

   . Paragangliomas arising in the head and neck: a morphologic review and genetic update. Surg Pathol Clin 2014;7:543–57 doi:10.1016/j.path.2014.08.007 pmid:26837554

   CrossRefPubMed
3. 3.↵
   1. Patel D,
   2. Phay JE,
   3. Yen TWF, et al

   . Update on pheochromocytoma and paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group, Part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma. Ann Surg Oncol 2020;27:1329–37 doi:10.1245/s10434-020-08220-3 pmid:32112212

   CrossRefPubMed
4. 4.↵
   1. Farrugia FA,
   2. Martikos G,
   3. Tzanetis P, et al

   . Pheochromocytoma, diagnosis and treatment: review of the literature. Endocr Regul 2017;51:168–81 doi:10.1515/enr-2017-0018 pmid:28858847

   CrossRefPubMed
5. 5.↵
   1. Neumann HP,
   2. Bausch B,
   3. McWhinney SR, et al

   . Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–66 doi:10.1056/NEJMoa020152 pmid:12000816

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Williams MD

   . Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol 2017;11:278–87 doi:10.1007/s12105-017-0803-4 pmid:28321772

   CrossRefPubMed
7. 7.↵
   1. Offergeld C,
   2. Brase C,
   3. Yaremchuk S, et al

   . Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo) 2012;67:(Suppl 1):19–28 doi:10.6061/clinics/2012(sup01)05] pmid:22584701

   CrossRefPubMed
8. 8.↵
   1. Woolen S,
   2. Gemmete JJ

   . Paragangliomas of the head and neck. Neuroimaging Clin N Am 2016;26:259–78 doi:10.1016/j.nic.2015.12.005 pmid:27154608

   CrossRefPubMed
9. 9.↵
   1. van Gils AP,
   2. van den Berg R,
   3. Falke TH, et al

   . MR diagnosis of paraganglioma of the head and neck: value of contrast enhancement. AJR Am J Roentgenol 1994;162:147–53 doi:10.2214/ajr.162.1.8273654 pmid:8273654

   CrossRefPubMed
10. 10.↵
    1. Thoeny HC,
    2. De KF,
    3. King AD

    . Diffusion-weighted MR imaging in the head and neck. Radiology 2012;263:19–32 doi:10.1148/radiol.11101821 pmid:22438440

    CrossRefPubMed
11. 11.↵
    1. Aschenbach R,
    2. Basche S,
    3. Vogl TJ, et al

    . Diffusion-weighted imaging and ADC mapping of head-and-neck paragangliomas: initial experience. Clin Neuroradiol 2009;19:215–19 doi:10.1007/s00062-009-9004-1 pmid:19705076

    CrossRefPubMed
12. 12.↵
    1. Tischler AS,
    2. deKrijger RR

    . 15 years of paraganglioma: pathology of pheochromocytoma and paraganglioma. Endocr Relat Cancer 2015;22:123c33 doi:10.1530/ERC-15-0261 pmid:26136457

    CrossRefPubMed
13. 13.↵
    1. Srinivasan A,
    2. Dvorak R,
    3. Perni K, et al

    . Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 2008;29:40–44 doi:10.3174/ajnr.A0743 pmid:17921228

    CrossRefPubMed
14. 14.↵
    1. Koontz NA,
    2. Wiggins RH 3rd..

    Differentiation of benign and malignant head and neck lesions with diffusion tensor imaging and DWI. AJR Am J Roentgenol 2017;208:1110–15 doi:10.2214/AJR.16.16486 pmid:28245145

    CrossRefPubMed
15. 15.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Güneş A,
    2. Ozgen B,
    3. Bulut E, et al

    . Magnetic resonance and diffusion weighted imaging findings of head and neck paragangliomas. Acta Oncologica Turcica 2019;52:416–23 doi:10.5505/aot.2019.19971

    CrossRef
17. 17.↵
    1. Yuan Y,
    2. Shi H,
    3. Tao X

    . Head and neck paragangliomas: diffusion weighted and dynamic contrast enhanced magnetic resonance imaging characteristics. BMC Med Imaging 2016;16:12 doi:10.1186/s12880-016-0114-3 pmid:26833065

    CrossRefPubMed
18. 18.↵
    1. Feng N,
    2. Zhang WY,
    3. Wu XT

    . Clinicopathological analysis of paraganglioma with literature review. World J Gastroenterol 2009;15:3003–08 doi:10.3748/wjg.15.3003 pmid:19554653

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Hiwatashi A,
    2. Kinoshita T,
    3. Moritani T, et al

    . Hypointensity on diffusion-weighted MRI of the brain related to T2 shortening and susceptibility effects. AJR Am J Roentgenol 2003;181:1705–09 doi:10.2214/ajr.181.6.1811705 pmid:14627600

    CrossRefPubMed
20. 20.↵
    1. Ahlawat S,
    2. Khandheria P,
    3. Grande FD, et al

    . Interobserver variability of selective region-of-interest measurement protocols for quantitative diffusion weighted imaging in soft tissue masses: comparison with whole tumor volume measurements. J Magn Reson Imaging 2016;43:446–54 doi:10.1002/jmri.24994 pmid:26174705

    CrossRefPubMed
21. 21.↵
    1. Han X,
    2. Suo S,
    3. Sun Y, et al

    . Apparent diffusion coefficient measurement in glioma: influence of region-of-interest determination methods on apparent diffusion coefficient values, interobserver variability, time efficiency, and diagnostic ability. J Magn Reson Imaging 2017;45:722–30 doi:10.1002/jmri.25405 pmid:27527072

    CrossRefPubMed
22. 22.↵
    1. Chang CA,
    2. Pattison DA,
    3. Tothill RW, et al

    . Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 2016;16;68:22 doi:10.1186/s40644-016-0084-2 pmid:27535829

    CrossRefPubMed
23. 23.↵
    1. Telischi FF,
    2. Bustillo A,
    3. Whiteman ML, et al

    . Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 2000;122:358–62 doi:10.1067/mhn.2000.102575 pmid:10699810

    CrossRefPubMed